United States, Oct. 20 -- The U.S. Food and Drug Administration granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.Patients with locally advanced rectal cancer often receive chemotherapy and radiation prior to surgery, which can affect bowel, urinary, and sexual function, as well as fertility. Surgery also carries risks of serious, sometimes life-threatening complications, including poor healing and leaks where the bowel is reconnected, and in some patients, permanent colostomy. Today's approval is for Jemperli used alone in adults with previously untreated st...